Pharming Group N.V. Files 6-K for Q2 Results

Ticker: PHAR · Form: 6-K · Filed: 2025-07-31T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, press-release, quarterly-report

TL;DR

Pharming Group dropped its Q2 earnings report on 7/31. Check the 6-K for details.

AI Summary

Pharming Group N.V. filed a Form 6-K on July 31, 2025, to furnish a press release regarding its second quarter financial results. The press release, dated July 31, 2025, is included as Exhibit 99.1 to this filing.

Why It Matters

This filing provides investors with timely updates on Pharming Group's financial performance for the second quarter of 2025, which can influence investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine submission of a press release containing financial results, with no new material events or significant changes indicated.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is to furnish a press release of Pharming Group N.V., dated July 31, 2025, which reports on the company's second quarter results.

What exhibit is included with this Form 6-K?

Exhibit 99.1, a press release from Pharming Group N.V. dated July 31, 2025, is furnished as part of this Form 6-K.

What period do the financial results in the press release cover?

The press release, furnished as Exhibit 99.1, reports on Pharming Group's second quarter results.

When was this Form 6-K filed?

This Form 6-K was filed on July 31, 2025.

What is Pharming Group N.V.'s principal executive office address?

Pharming Group N.V.'s principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.

From the Filing

0001828316-25-000034.txt : 20250731 0001828316-25-000034.hdr.sgml : 20250731 20250731060259 ACCESSION NUMBER: 0001828316-25-000034 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250731 FILED AS OF DATE: 20250731 DATE AS OF CHANGE: 20250731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 251169122 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 a2025hy1pressrelease.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated July 31, 2025. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports second quarter and first half 2025 financial results and provides business update SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: July 31, 2025 2 Pharming Group reports second quarter and first half 2025 financial results and provides business update • Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth • RUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribers • Joenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptake • Second quarter operating profit amounted to US$10.8 million compared to a US$3.1 million loss in the second quarter 2024 • Study published in leading peer-reviewed journal Cell identifies new variants leading to PI3Kδ pathway hyperactivity, supporting reclassification of VUS patients to APDS and suggesting up to a 100-fold increase in APDS prevalence • Submitted new drug application for leniolisib for the treatment of APDS in Japan • 2025 total revenue guidance raised to US$335 million - US$350 million, up from prior US$325 million - US$340 million • Overall cash and marketable securities increased to US$130.8 million at the end of the second quarter 2025 from US$108.9 million at the end of the first quarter 2025, primarily due to cash generated from operations • Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) Leiden, the Netherlands, July 31, 2025: Pharming Group N.V. (“

View on Read The Filing